Belantamab plus daratumumab, pomalidomide, and dexamethasone for myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Eyes & vision, Heart & circulation, Immune system & allergy clinical trials.
This early-phase study tests whether adding belantamab mafodotin to a combination treatment (daratumumab, pomalidomide, and dexamethasone) is safe and can shrink multiple myeloma in people whose disease is back or not responding. It is for people who have only had one prior treatment and cannot respond to lenalidomide.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have a confirmed diagnosis of multiple myeloma.
- Your myeloma must be measurable (for example, higher abnormal protein levels in urine or blood).
- Your heart, liver, and kidney blood test results must be within allowed ranges, and you must not have serious uncontrolled kidney problems.
- You must have had only one prior treatment line (including lenalidomide), and your myeloma must be “lenalidomide-refractory” (not responding or relapsing within 60 days).
- You must have good enough strength for treatment (ECOG performance status 0–2).
- You must not have certain conditions, including moderate-to-severe nerve pain (neuropathy), recent major surgery, active infection, serious uncontrolled heart/lung issues, or prior treatment with daratumumab, pomalidomide, or belantamab (with limited exceptions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests how safe and effective belantamab mafodotin is when combined with lenalidomide and dexamethasone, plus a medicine called nirogacestat, in people with newly diagnosed multiple myeloma who cannot have stem cell transplant. It may help shrink the cancer and improve outcomes, while doctors track side effects.
This study tests the safety and effectiveness of the drug belantamab, alone or with other treatments, for people with multiple myeloma that has come back or stopped responding to previous treatments.
This Phase 2 study tests whether belantamab mafodotin combined with carfilzomib, pomalidomide, and dexamethasone can better treat multiple myeloma that has come back. It may help people who have already tried other myeloma treatments but whose cancer has progressed again.
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
This trial tests different dosing schedules of three drugs (belantamab mafodotin, bortezomib, and dexamethasone) together to treat multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find a dosing plan that works well and is tolerable for patients.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.